AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05740163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg product including egg white and yolk allergens
Description: Egg product either meatball or bread roll or bun including egg white and yolk allergens delivered orally in increasing dosages daily.
Study NCT04330391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote dietitian supervised weight loss intervention and mobile app
Description: Please see intervention arm description for more details.
Study NCT01529515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 175 mg eq.
Description: Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study NCT01529515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 263 mg eq.
Description: Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study NCT01529515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 350 mg eq.
Description: Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study NCT01529515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP3M 525 mg eq.
Description: Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study NCT01529515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (20% Intralipid emulsion)
Description: Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
Study NCT04071262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT04071262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally
Study NCT04071262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Administered orally
Study NCT01293630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01293630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT01293630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study NCT02664649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight \<60 kg, serum creatinine ≥1.5 mg/dL \[133 μMol/L\].~- Also, subjects with severe renal insufficiency \[calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min\] will take apixaban 2.5 mg tablets orally twice daily
Study NCT02664649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: VKA or Antiplatelet therapy
Study NCT05440591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10mg tablets
Study NCT05440591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: Metformin 500 mg tablets twice daily
Study NCT03758274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT by Phone to Promote Treatment
Description: Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
Study NCT03758274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment
Description: The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
Study NCT04081168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiotherapy
Description: Patients will undergo Stereotactic Body Radiotherapy (SBRT)
Study NCT04081168 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Patients will undergo Microwave Ablation (MWA)
Study NCT02753023 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention related
Study NCT05440591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin / metFORMIN Pill
Description: Combination pill
Study NCT02079831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity.
Study NCT02079831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher protein
Description: The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
Study NCT02079831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
Study NCT02534935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rLP2086 vaccine
Description: 60 mcg or 120mcg at 0, 2 and 6 months
Study NCT02534935 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric HAV vaccine
Description: 0.5-mL dose at months 0 and 6. Normal saline at month 2.
Study NCT03912766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum copeptin
Description: routine surgical method using resectoscope inserted into the urinary bladder
Study NCT02345850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate
Description: Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Study NCT02345850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilized CD34-selected Peripheral Blood Stem Cell graft
Description: Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Study NCT02345850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unmanipulated Bone Marrow Graft with Cyclophosphamide
Description: Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
Study NCT02345850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Study NCT02345850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
Study NCT02345850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be administered at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
Study NCT02460354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg pill dispensed once orally
Study NCT01239381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy-proton
Description: Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
Study NCT02665351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peramivir
Description: The two regimens of Peramivir were compared
Study NCT02220855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT02442310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone delayed release tablet formulation
Description: Deferiprone 600 mg delayed release tablet formulation
Study NCT01949662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: 3 mg by vein one time only.
Study NCT01949662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo consisting of preservative free 0.9% normal saline given one time by vein.
Study NCT01949662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Description: 8 mg/day by vein.
Study NCT01949662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol decanoate
Description: 8 mg/day by vein.
Study NCT01949662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
Study NCT00690131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTSCS
Description: BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
Study NCT01539057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen
Description: The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts
Study NCT01539057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
Study NCT00822250 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: analysis of pigmentation
Description: cutting hair, skin description, skin biopsy for only 4 patients
Study NCT02442310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone oral solution
Description: Deferiprone 100 mg/mL oral solution
Study NCT02526745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with high doses of virus content between 4.7～5.0 lgPFU
Study NCT02526745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with low doses of virus content between 4.7～5.0 lgPFU
Study NCT02526745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with high doses of virus content between 4.3～5.0 lgPFU
Study NCT02526745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with middle doses of virus content between 4.3～5.0 lgPFU
Study NCT02526745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the vaccine with low doses of virus content between 4.3～5.0 lgPFU
Study NCT03569774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-lung ventilation with individualized PEEP
Description: During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
Study NCT01949662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
Study NCT02526745 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02373202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:solution
Study NCT02373202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT05080855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified Millard technique vs Tennison-Randall technique
Description: evaluate the quantitative (anthropometric) assessment of modified Millard technique in comparison to Tennison-Randall technique in unilateral cleft lip (ucl) repair. Inclusion criteria: Patient with ages from 2 months old to 6 months old, Patient with unilateral cleft lip complete or incomplete type.
Study NCT03784599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Infusion
Study NCT03784599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Tablet
Study NCT00986401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium Chloride (Sanctura XR®)
Description: extended release, 60 mg, oral daily
Study NCT00986401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (Glucophage®)
Description: immediate release, 500mg
Study NCT03927235 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transbronchial Cryobiopsy
Description: Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
Study NCT03927235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy
Description: Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
Study NCT05305222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous (IV) Infusion
Study NCT05305222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV) Infusion
Study NCT00064259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00064259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00064259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02373202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT03547739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home visits
Description: If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
Study NCT01180426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-2797
Description: 120mg once daily oral for 48 weeks
Study NCT02373202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bucillamine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT02373202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT02373202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT02392247 — intervention group
Intervention type: DEVICE
Intervention: Coagulation function
Description: Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
Study NCT03108833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Prourokinase
Description: The drug is used for intravenous thrombolysis therapy
Study NCT03108833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: The drug is used for intravenous thrombolysis therapy
Study NCT01411228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Description: Taliglucerase alfa for infusion every two weeks for 24 months
Study NCT03415191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
Study NCT03415191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
Study NCT02393508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Human Red Blood Cells
Description: Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
Study NCT02393508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aged Human Red Blood Cells
Description: Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
Study NCT00660998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 1h before sexual intercourse
Study NCT00660998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo